Open-label Single Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of nemolizumab in Pediatric Patients with Atopic Dermatitis.
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
Price : $35 *
At a glance
- Drugs Nemolizumab (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Maruho
- 11 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Oct 2017 New trial record